Compare Stocks: MTNB, PHIO, CMMB, and VTGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMMB Chemomab Therapeutics	$1.27 -1.9%	$2.10	$1.05 ▼ $3.45	$9.17M	0.74	97,393 shs	9,080 shs
MTNB Matinas Biopharma	$2.37 -2.1%	$2.89	$2.26 ▼ $27.90	$2.32M	2.08	136,148 shs	24,656 shs
PHIO Phio Pharmaceuticals	$0.87 -5.9%	$1.05	$0.81 ▼ $4.19	$10.12M	0.84	1.42 million shs	91,131 shs
VTGN VistaGen Therapeutics	$0.20 -6.1%	$0.25	$0.20 ▼ $5.14	$8.88M	0.33	4.95 million shs	558,431 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMMB Chemomab Therapeutics	0.00%	-7.19%	-47.77%	-17.31%	-61.83%
MTNB Matinas Biopharma	-2.42%	-14.49%	+0.83%	-53.05%	-91.51%
PHIO Phio Pharmaceuticals	-2.51%	-4.86%	-9.24%	-10.12%	-58.67%
VTGN VistaGen Therapeutics	+3.10%	-13.48%	-9.78%	-7.07%	-94.68%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMMB Chemomab Therapeutics	$1.27 -1.9%	$2.10	$1.05 ▼ $3.45	$9.17M	0.74	97,393 shs	9,080 shs
MTNB Matinas Biopharma	$2.37 -2.1%	$2.89	$2.26 ▼ $27.90	$2.32M	2.08	136,148 shs	24,656 shs
PHIO Phio Pharmaceuticals	$0.87 -5.9%	$1.05	$0.81 ▼ $4.19	$10.12M	0.84	1.42 million shs	91,131 shs
VTGN VistaGen Therapeutics	$0.20 -6.1%	$0.25	$0.20 ▼ $5.14	$8.88M	0.33	4.95 million shs	558,431 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMMB Chemomab Therapeutics	0.00%	-7.19%	-47.77%	-17.31%	-61.83%
MTNB Matinas Biopharma	-2.42%	-14.49%	+0.83%	-53.05%	-91.51%
PHIO Phio Pharmaceuticals	-2.51%	-4.86%	-9.24%	-10.12%	-58.67%
VTGN VistaGen Therapeutics	+3.10%	-13.48%	-9.78%	-7.07%	-94.68%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMMB Chemomab Therapeutics	1.50	Reduce	N/A	N/A
MTNB Matinas Biopharma	0.00	N/A	N/A	N/A
PHIO Phio Pharmaceuticals	2.00	Hold	$14.00	1,473.03% Upside
VTGN VistaGen Therapeutics	1.80	Reduce	$0.95	372.64% Upside

Current Analyst Ratings Breakdown

Latest MTNB, PHIO, CMMB, and VTGN Analyst Ratings

Date	Company	Brokerage	Action	Rating
10/15/2026	PHIO Phio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/16/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/2/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/31/2026	VTGN VistaGen Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
8/26/2026	PHIO Phio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/19/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/5/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
7/17/2026	PHIO Phio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)

(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$2.00 per share	N/A
MTNB Matinas Biopharma	$1.10M	2.16	N/A	N/A	$11.30 per share	0.22
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	$1.87 per share	N/A
VTGN VistaGen Therapeutics	$1.27M	7.02	N/A	N/A	$0.90 per share	0.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMMB Chemomab Therapeutics	-$8.99M	-$2.13	N/A	N/A	N/A	N/A	-92.14%	-82.05%	11/6/2026 (Estimated)
MTNB Matinas Biopharma	-$10.35M	-$3.89	N/A	N/A	N/A	N/A	-166.11%	-102.20%	N/A
PHIO Phio Pharmaceuticals	-$8.70M	-$1.29	N/A	N/A	N/A	N/A	-87.41%	-79.76%	11/12/2026 (Estimated)
VTGN VistaGen Therapeutics	-$69.68M	-$1.66	N/A	N/A	N/A	-2,702.64%	-152.59%	-117.45%	11/12/2026 (Estimated)

Latest MTNB, PHIO, CMMB, and VTGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	PHIO Phio Pharmaceuticals	-$0.36	N/A	N/A	N/A	N/A	N/A
11/12/2026	Q2 2027	VTGN VistaGen Therapeutics	-$0.37	N/A	N/A	N/A	$0.50 million	N/A
11/6/2026	Q3 2026	CMMB Chemomab Therapeutics	-$0.01	N/A	N/A	N/A	N/A	N/A
8/20/2026	Q2 2026	CMMB Chemomab Therapeutics	-$0.15	-$0.27	-$0.12	-$0.24	N/A	N/A
8/14/2026	Q1 2027	VTGN VistaGen Therapeutics	-$0.3650	-$0.30	+$0.0650	-$0.30	$0.50 million	$1.48 million
8/13/2026	Q2 2026	MTNB Matinas Biopharma	N/A	-$3.15	N/A	-$3.15	N/A	N/A
8/6/2026	Q2 2026	PHIO Phio Pharmaceuticals	-$0.36	-$0.36	N/A	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
MTNB Matinas Biopharma	N/A	N/A	N/A	N/A	N/A
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VTGN VistaGen Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMMB Chemomab Therapeutics	N/A	6.41	6.41
MTNB Matinas Biopharma	N/A	0.85	0.85
PHIO Phio Pharmaceuticals	N/A	8.39	8.39
VTGN VistaGen Therapeutics	N/A	3.07	3.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMMB Chemomab Therapeutics	46.05%
MTNB Matinas Biopharma	11.77%
PHIO Phio Pharmaceuticals	57.31%
VTGN VistaGen Therapeutics	78.39%

Insider Ownership

Company	Insider Ownership
CMMB Chemomab Therapeutics	11.91%
MTNB Matinas Biopharma	4.60%
PHIO Phio Pharmaceuticals	3.52%
VTGN VistaGen Therapeutics	2.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMMB Chemomab Therapeutics	12	7.25 million	6.38 million	Not Optionable
MTNB Matinas Biopharma	2	980,000	935,000	N/A
PHIO Phio Pharmaceuticals	6	11.62 million	11.21 million	Not Optionable
VTGN VistaGen Therapeutics	41	44.38 million	43.08 million	Optionable

MTNB, PHIO, CMMB, and VTGN Headlines

Recent News About These Companies

VistaGen Therapeutics (NASDAQ:VTGN) Share Price Crosses Below 50 Day Moving Average - Should You Sell?

October 7, 2026 | americanbankingnews.com

2 Falling Stocks Call Traders Are Targeting Today

September 25, 2026 | schaeffersresearch.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Codexis (CDXS) and VistaGen Therapeutics (VTGN)

September 24, 2026 | theglobeandmail.com

Vistagen Reports Positive Findings Supporting Fasedienol's Potential in Very Severe Social Anxiety Disorder

September 24, 2026 | globenewswire.com

Vistagen Reports Preliminary Data From Fasedienol Phase 3 Extension Study; Stock Up

September 22, 2026 | rttnews.com

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

September 22, 2026 | globenewswire.com

VistaGen Stockholders Reaffirm Board, Governance and Oversight

September 11, 2026 | tipranks.com

Vistagen to Present at Psych Congress 2026

September 10, 2026 | globenewswire.com

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

August 14, 2026 | globenewswire.com

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

August 6, 2026 | globenewswire.com

SRX Global (NYSE American: SRXH) Acquires Stake in Vistagen Therapeutics

August 4, 2026 | markets.businessinsider.com

Vistagen Appoints Douglas J. Williamson to its Board of Directors

July 31, 2026 | globenewswire.com

Stifel Nicolaus Remains a Hold on VistaGen Therapeutics (VTGN)

July 18, 2026 | theglobeandmail.com

Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?

July 15, 2026 | insidermonkey.com

VistaGen Therapeutics (VTGN) Receives a Rating Update from a Top Analyst

July 4, 2026 | theglobeandmail.com

Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript

June 30, 2026 | seekingalpha.com

Vistagen's anxiety disorder drug misses main goal in late-stage trial, shares plummet

June 30, 2026 | reuters.com

Vistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term Growth

June 17, 2026 | tipranks.com

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

June 15, 2026 | businesswire.com

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

June 9, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTNB, PHIO, CMMB, and VTGN Company Descriptions

Chemomab Therapeutics NASDAQ:CMMB

$1.26 -0.03 (-2.25%)

As of 04:00 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Matinas Biopharma NYSEAMERICAN:MTNB

$2.37 -0.05 (-2.07%)

As of 04:10 PM Eastern

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Phio Pharmaceuticals NASDAQ:PHIO

$0.87 -0.05 (-5.91%)

Closing price 03:59 PM Eastern

Extended Trading

$0.90 +0.03 (+3.20%)

As of 06:03 PM Eastern

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

VistaGen Therapeutics NASDAQ:VTGN

$0.20 -0.01 (-6.10%)

Closing price 04:00 PM Eastern

Extended Trading

$0.20 +0.00 (+0.50%)

As of 06:31 PM Eastern

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MTNB, PHIO, CMMB, and VTGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MTNB, PHIO, CMMB, and VTGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MTNB, PHIO, CMMB, and VTGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTNB, PHIO, CMMB, and VTGN Company Descriptions

Chemomab Therapeutics NASDAQ:CMMB

Matinas Biopharma NYSEAMERICAN:MTNB

Phio Pharmaceuticals NASDAQ:PHIO

VistaGen Therapeutics NASDAQ:VTGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MTNB, PHIO, CMMB, and VTGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MTNB, PHIO, CMMB, and VTGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MTNB, PHIO, CMMB, and VTGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTNB, PHIO, CMMB, and VTGN Company Descriptions

Chemomab Therapeutics NASDAQ:CMMB

Matinas Biopharma NYSEAMERICAN:MTNB

Phio Pharmaceuticals NASDAQ:PHIO

VistaGen Therapeutics NASDAQ:VTGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools